top of page

News and Events

Image-empty-state.png

Kalbe Launches Anemia Efepoetin Alfa, a Drug for Patients with Chronic Kidney Diseases

Through its subsidiaries of PT Kalbe Genexine Biologics (KGbio) and PT Finusolprima Farma Internasional (FIMA)...

Read More
Image-empty-state.png

Kalbe Launches Serplulimab, Lung Cancer Therapeutic Drug

PT Kalbe Farma Tbk (Kalbe) is currently the only domestic pharmaceutical company...

Read More
Image-empty-state.png

KGbio Received Market Approval for Efesa

PT Kalbe-Genexine Biologis (KGbio) received a distribution permit from BPOM for Efesa...

Read More
Image-empty-state.png

Kalbe Establishes Strategic Cooperation with Henlius for Lung Cancer Therapeutic Drug (Serplulimab) in the Middle East and North Africa Territories

PT Kalbe Farma Tbk (Kalbe) through its subsidiary PT Kalbe Genexine Biologics (KGbio)...

Read More
Image-empty-state.png

Press Conference on Rituxikal Distribution Permit Approval by BPOM

On 28 December 2022, BPOM has issued a distribution permit for Rituxikal as the first monoclonal antibody product...

Read More
Image-empty-state.png

Trazher 150 mg Powder for Concentrate for Solution for Infusion is approved in Singapore

On 19 Oct 2022, Trazher 150 mg Powder for Concentrate for...

Read More
Image-empty-state.png

Indonesia's FDA (BPOM) has approved new indication for Theracim

Indonesia’s FDA (BPOM) has approved new indication “Locally advanced non-nasopharyngeal...

Read More
Image-empty-state.png

Thailand FDA has approved Rituxikal (Rituximab Biosimilar)

On 11 May 2022, Thailand FDA has approved Rituxikal (Rituximab Biosimilar). By this milestone, ...

Read More
Image-empty-state.png

General Atlantic US Invests US$55 Million in Kalbe Genexine Biologics

General Atlantic, a leading worldwide growth equity firm that invests in and supports early-stage companies...

Read More
bottom of page